hypophosphatemia/tyrosine

Linkul este salvat în clipboard

Alegeți tipul de sortare

Pagină 1 din 32 rezultate

[Investigation and Measurement of Hypophosphatemia Induced by Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia].

Numai utilizatorii înregistrați pot traduce articole

We retrospectively investigated hypophosphatemia induced byty rosine kinase inhibitors(TKIs), in patients with chronic myeloid leukemia. Subjects evaluated were 14, 11, and 8 patients who received TKIs(imatinib, dasatinib and nilotinib), respectively, at the Department of Hematology in Ichinomiya

A Case of Hypophosphatemia with Increased Urinary Excretion of Phosphorus Associated with Ibrutinib.

Numai utilizatorii înregistrați pot traduce articole

Ibrutinib, an irreversible oral inhibitor of Bruton's tyrosine kinase, has been used in the treatment of patients with multiple hematologic malignancies. A 59-year-old male with chronic lymphocytic leukemia was treated with 420 mg/day of ibrutinib. No evidence of bruising or diarrhea was noted. The

Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.

Numai utilizatorii înregistrați pot traduce articole

BACKGROUND Nilotinib, a second-generation tyrosine kinase inhibitor (TKI) formerly known as AMN107, was approved by the US Food and Drug Administration (FDA) on October 29, 2007, for the treatment of adult patients with chronic-phase (CP) and accelerated-phase (AP) Philadelphia chromosome-positive

Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies.

Numai utilizatorii înregistrați pot traduce articole

Tyrosine kinase inhibitors (TKIs) are at the forefront of molecular-targeted therapies for cancer. With the advent of imatinib for the treatment of chronic myelogenous leukemia, a new wave of small-molecule therapeutics redefined the oncologic treatment to become chronically administered medications

Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine-kinase inhibitor refractory gastrointestinal stromal tumors.

Numai utilizatorii înregistrați pot traduce articole

Polyclonal emergence of KIT secondary mutations is a main mechanism of imatinib progression in gastrointestinal stromal tumor (GIST). Approved KIT inhibitors sunitinib and regorafenib have complementary activity against KIT resistance mutations. Preclinical evidence suggests that rapid

Real-life treatment of metastatic colorectal cancer with regorafenib: a single-centre review.

Numai utilizatorii înregistrați pot traduce articole

BACKGROUND Various tyrosine kinase signalling pathways affect the development and progression of colorectal cancer (crc). In clinical trials, regorafenib has been associated with a survival benefit in metastatic crc (mcrc). We assessed the safety and efficacy of regorafenib in real-world

[Mutation analysis of FAH gene in patients with tyrosinemia type 1].

Numai utilizatorii înregistrați pot traduce articole

OBJECTIVE To investigate the clinical features and mutations of the FAH gene. METHODS Clinical records of two cases were collected, and diagnosis was made according to the diagnostic criteria of the International Organization for Rare Disorders (NORD). Genomic DNA was extracted from peripheral blood

Dysregulation of bone remodeling by imatinib mesylate.

Numai utilizatorii înregistrați pot traduce articole

Imatinib mesylate is a rationally designed tyrosine kinase inhibitor that has revolutionized the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Although the efficacy and tolerability of imatinib are a vast improvement over conventional chemotherapies, the drug exhibits

Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.

Numai utilizatorii înregistrați pot traduce articole

OBJECTIVE Sorafenib and erlotinib are potent, orally administered receptor tyrosine kinase inhibitors with antiproliferative and antiangiogenic activities. Given their inhibitory target profile and efficacy as single agents, the combination of these drugs is of considerable interest in solid

A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.

Numai utilizatorii înregistrați pot traduce articole

OBJECTIVE To determine the efficacy and safety of single agent sorafenib, an oral multi-targeted tyrosine kinase inhibitor, in patients with advanced uterine carcinoma and carcinosarcoma. METHODS This multi-institutional non-randomized phase II trial enrolled two cohorts: patients with uterine

Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.

Numai utilizatorii înregistrați pot traduce articole

OBJECTIVE To review the common and serious toxicities associated with the use of tyrosine kinase inhibitors such as sorafenib and sunitinib and mTOR inhibitor temsirolimus, and to outline the most recent toxicity management guidelines. RESULTS Common grade 3 or 4 side effects with sorafenib include

Supplements containing amino acids and keto acids in the treatment of chronic uremia.

Numai utilizatorii înregistrați pot traduce articole

Three mixtures containing varying proportions of threonine, tyrosine, and the ornithine, lysine, and histidine salts of branched-chain keto acids have been tested as dietary supplements to a 20- to 25-g mixed-quality protein diet in patients with severe chronic uremia. Two of the three supplements

Expanding the phenotype of hawkinsinuria: new insights from response to N-acetyl-L-cysteine.

Numai utilizatorii înregistrați pot traduce articole

Hawkinsinuria is a rare disorder of tyrosine metabolism that can manifest with metabolic acidosis and growth arrest around the time of weaning off breast milk, typically followed by spontaneous resolution of symptoms around 1 year of age. The urinary metabolites hawkinsin, quinolacetic acid, and

Use of cinacalcet and sunitinib to treat hypercalcaemia due to a pancreatic neuroendocrine tumor.

Numai utilizatorii înregistrați pot traduce articole

Neuroendocrine tumors (NETs) can secrete hormones, including ectopic secretions, but they have been rarely associated with malignant hypercalcemia. A 52-year-old man with a history of diabetes mellitus was diagnosed with a pancreatic tumor. A pancreatic biopsy confirmed a well-differentiated

Long-term imatinib therapy promotes bone formation in CML patients.

Numai utilizatorii înregistrați pot traduce articole

Imatinib inhibits tyrosine kinases important in osteoclast (c-Fms) and osteoblast (platelet-derived growth factor receptor [PDGF-R], c-Abl) function, suggesting that long-term therapy may alter bone homeostasis. To investigate this question, we measured the trabecular bone volume (TBV) in iliac

Anterior
1
2
3
Următor →

Alăturați-vă paginii
noastre de facebook

Herbal & Natural Medicine

Cea mai completă bază de date cu plante medicinale susținută de știință

Funcționează în 55 de limbi
Cure pe bază de plante susținute de știință
Recunoașterea ierburilor după imagine
Harta GPS interactivă - etichetați ierburile în locație (în curând)
Citiți publicațiile științifice legate de căutarea dvs.
Căutați plante medicinale după efectele lor
Organizați-vă interesele și rămâneți la curent cu noutățile de cercetare, studiile clinice și brevetele

Tastați un simptom sau o boală și citiți despre plante care ar putea ajuta, tastați o plantă și vedeți boli și simptome împotriva cărora este folosit.
* Toate informațiile se bazează pe cercetări științifice publicate